Testing a new COVID-19 vaccine booster for safety and immune response
A Phase 1/2 Multicenter, Randomized Study of the Safety and Immunogenicity of a Sub-unit Protein CD40.RBDv Bivalent COVID-19 Vaccine, Adjuvanted or Not, as a Booster in Volunteers.
This study is testing a new COVID-19 vaccine booster to see if it’s safe and helps healthy people build a strong immune response compared to an approved vaccine.
Quick facts
| Phase | Phase1; Phase2 |
|---|---|
| Study type | Interventional |
| Enrollment | 215 (estimated) |
| Ages | 18 Years to 84 Years |
| Sex | All |
| Sponsor | ANRS, Emerging Infectious Diseases Government |
| Locations | 2 sites (Créteil and 1 other locations) |
| Trial ID | NCT06255626 on ClinicalTrials.gov |
What this trial studies
This clinical trial evaluates the safety and immunogenicity of the CD40.RBDv bivalent COVID-19 vaccine, with and without an adjuvant, as a booster in healthy volunteers. Participants will be randomly assigned to receive either the CD40.RBDv vaccine or an approved mRNA vaccine, with different dosing regimens across four cohorts. The study aims to assess the vaccine's safety profile and its ability to elicit an immune response. The trial is structured in two parts, with follow-up assessments to determine the need for additional doses.
Who should consider this trial
Good fit: Ideal candidates are healthy adults aged 18 to 85 who have received prior COVID-19 vaccinations.
Not a fit: Patients who have not received any prior COVID-19 vaccinations or those with acute febrile infections may not benefit from this study.
Why it matters
Potential benefit: If successful, this vaccine could provide a new booster option for enhancing immunity against COVID-19.
How similar studies have performed: Other studies have shown promising results with similar vaccine approaches, but this specific formulation is novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Healthy volunteers Age ≥18 and \<85 * Able to understand and comply with planned study procedures and sign an informed consent before performance of any study-related screening procedures * Who has received a primary series of vaccination and ≥ 1 booster(s) of COVID-19 mRNA vaccination(s) with the last boost at least 6 months prior to the inclusion in the study * Subjects has adequate organ functions, evidenced by normal ALT, AST, and alkaline phosphatase * Normal haematology lab values * Negative virology assessment * Normal Urine testing * Volunteers must meet the eligibility criteria in the approved package labelling of the active comparator * For women of childbearing potential: use of an effective contraceptive method and negative pregnancy test. For male participants, use of an effective method of contraception with their partner Exclusion Criteria: * Acute febrile infection within the previous 72 hours and/or presenting symptoms suggestive of COVID-19 or SARS CoV 2 infection within the previous 28 days * Immunosuppressive medications received within last three months before first IMP administration or within 6 months for chemotherapies * Immunoglobulins within 90 days before first IMP administration * Blood products within 120 days before first IMP administration * Any medical condition, such as cancer, that might impair the immune response * Use of any experimental therapy * Intent to participate in another study of an investigational research agent within 4 weeks prior to the enrolment visit or until the end of the study * Currently pregnant or breastfeeding * History of severe adverse events following vaccine administration * Any bleeding disorder considered as a contraindication to an intramuscular injection * A condition that requires active medical intervention or monitoring to avert grave danger to Asthma other than mild, well-controlled asthma. * Hypertension * BMI ≥ 40 kg/m2; ≤ 18 kg/m2; or BMI ≥ 35 kg/m2 with 2 or more of the following: age \> 45, current smoker, known hyperlipidemia, blood pressure is defined as consistently ≥ 140 mm Hg systolic and ≥ 90 mm Hg diastolic * Malignancy * Asplenia * Seizure disorder * History of hereditary angioedema acquired angioedema, or idiopathic angioedema * History of myocarditis, pericarditis, cardiomyopathy, congestive heart failure with permanent sequelae, clinically significant arrhythmia (including arrhythmia requiring medication, treatment, or clinical follow-up * History of autoimmune disease * Any medical, occupational, or other condition that, in the judgment of the investigator, would interfere with or serve as a contraindication to protocol adherence * Psychiatric condition that precludes compliance with the protocol. * Live attenuated vaccines received within 30 days before first IMP administration or scheduled within 28 days after one of the last injection according to the protocol * Vaccines that are not live attenuated vaccines and were received within 21 days prior to first IMP administration * Allergy treatment with antigen injections within 30 days before first IMP administration and until the end of the study
Where this trial is running
Créteil and 1 other locations
- Hopital Henri Mondor — Créteil, France (Recruiting)
- Hôpital Cochin — Paris, France (Recruiting)
Study contacts
- Study coordinator: Yves Levy, MD
- Email: yves.levy@aphp.fr
- Phone: +33149814442
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.